Drugs / Gliclazide
Gliclazide
also known as
Diamicron · Bilxona · Dacadis mr · Diaglyk · Diamicron mr · Edicil · Gliclazida · gliclazide MR · +14 more
Trials 23
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04198948 | Mar → Aug 2019 | type 2 diabetes mellitus | University of Sarajevo | Completed | No outcome recorded |
| Phase 1 | NCT03467971 | Mar → Apr 2018 | — | Merck KGaA, Darmstadt, Germany | Completed | Mixed |
| Phase 1 | NCT02777671 | Oct → Dec 2007 | epilepsy | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT00169624 | Oct 2005 → ? | — | Hospices Civils de Lyon | Terminated | No outcome recorded |
| Phase 3 | NCT00145925 | Jun 2001 → Mar 2008 | type 2 diabetes mellitus | The George Institute | Completed | Mixed |
| Phase 3 | NCT00379769 | Apr 2001 → Dec 2008 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 411 trials · 1 met primary · 2 missed | ||||||
| Phase 4 | NCT06613750 | Jun 2024 | hyperglycemia, type 2 diabetes mellitus | Zhibin Xu | Completed | No outcome recorded |
| Phase 4 | NCT03804411 | Aug 2017 → Mar 2020 | type 2 diabetes mellitus | Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health | Unknown | No outcome recorded |
| Phase 4 | NCT02201602 | Aug 2014 → Jun 2016 | type 2 diabetes mellitus | Khoo Teck Puat Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01758380 | Jan → Sep 2013 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 4 | NCT01709305 | Nov 2012 → Apr 2015 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 4 | NCT01426737 | Apr 2011 → Jan 2013 | type 2 diabetes mellitus | University of Zurich | Unknown | No outcome recorded |
| Phase 4 | NCT00736515 | Oct 2008 → Aug 2011 | type 2 diabetes mellitus | Servier (Tianjin) Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 4 | NCT00700856 | Sep 2008 → Dec 2018 | cardiovascular disorder, type 2 diabetes mellitus | Italian Society of Diabetology | Unknown | Missed primary |
| Phase 4 | NCT00738088 | Jun 2007 → Mar 2011 | type 2 diabetes mellitus | NHS Tayside | Terminated | No outcome recorded |
| Phase 4 | NCT00367055 | Oct 2004 → Oct 2008 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | Missed primary |
| Phase 4 | NCT00225342 | — | intermediate coronary syndrome, type 2 diabetes mellitus | University of Glasgow | Withdrawn | No outcome recorded |
| Phase not applicable6 trials · 1 met primary | ||||||
| — | NCT06085703 | Apr 2024 → Jun 2025 | cognitive impairment with or without cerebellar ataxia, type 2 diabetes mellitus | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Completed | Met primary |
| — | NCT06217887 | May 2020 → Feb 2024 | cognitive disorder, type 2 diabetes mellitus | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
| — | NCT04192292 | Oct 2019 → Dec 2020 | type 2 diabetes mellitus | University of Dundee | Completed | No outcome recorded |
| — | NCT03705195 | Aug 2018 → Jun 2019 | type 2 diabetes mellitus | University of Dundee | Completed | No outcome recorded |
| — | NCT00978263 | Feb 2009 → Dec 2011 | diabetes mellitus | Chongqing Medical University | Completed | No outcome recorded |
| — | NCT00464594 | Apr 2007 → ? | diabetes mellitus | Japan Early Diabetes Intervention Study Group | Unknown | No outcome recorded |
| Comparator or background therapy30 trials | ||||||
| Phase 0 | NCT06796660 Background | Sep 2025 → Dec 2027 expected | chronic kidney disease | Liu Zhanghong | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT01991197 Comparator | Apr 2014 → Jan 2016 | psoriasis, type 2 diabetes mellitus | University College Dublin | Completed | Missed primary |
| Phase 2 | NCT00830297 Comparator | Jan 2009 → Dec 2010 | hyperglycemia | Marcus Saemann | Completed | No outcome recorded |
| Phase 3 | NCT03313661 Comparator | Oct 2017 → Oct 2020 | type 2 diabetes mellitus | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT01590771 Background | Jul 2012 → Jun 2014 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT01584232 Background | Apr 2012 → Jul 2013 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT01242215 Background | Sep 2010 → Apr 2012 | type 2 diabetes mellitus | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT01340768 Comparator | Jun 2010 → Sep 2011 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT01076075 Background | Jun 2010 → Jul 2011 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT00102388 Comparator | Jan 2005 → Mar 2008 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT00102466 Comparator | Jan 2005 → Jan 2009 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT06449235 Comparator | Sep 2024 → Apr 2025 overdue | type 2 diabetes mellitus | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT03819790 Comparator | Oct 2018 → Nov 2019 | type 2 diabetes mellitus | LMC Diabetes & Endocrinology Ltd. | Completed | Missed primary |
| Phase 4 | NCT03433248 Comparator | Nov 2017 → Jun 2021 | type 2 diabetes mellitus | M.H.H. Kramer | Unknown | No outcome recorded |
| Phase 4 | NCT02694263 Comparator | Jul 2016 → Sep 2018 | type 2 diabetes mellitus | University of Leicester | Completed | No outcome recorded |
| Phase 4 | NCT02682563 Comparator | Feb 2016 → Sep 2018 | diabetic kidney disease, type 2 diabetes mellitus | M.H.H. Kramer | Completed | No outcome recorded |
| Phase 4 | NCT02610088 Comparator | Nov 2015 → Jul 2018 | diabetes mellitus | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02526810 Background | Jul 2015 → Aug 2016 | type 2 diabetes mellitus | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 4 | NCT03068065 Comparator | May → Nov 2014 | NAFLD1, type 2 diabetes mellitus | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Completed | No outcome recorded |
| Phase 4 | NCT02092597 Comparator | Oct 2013 → Oct 2015 | type 2 diabetes mellitus | Charles University, Czech Republic | Completed | No outcome recorded |
| Phase 4 | NCT01847144 Comparator | Apr 2013 → Feb 2015 | type 2 diabetes mellitus | Royal Devon and Exeter NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT01679899 Comparator | Dec 2012 → Oct 2015 | osteoporosis, type 2 diabetes mellitus | Centro de Diabetes Curitiba Ltda | Completed | Missed primary |
| Phase 4 | NCT01269996 Comparator | May 2011 → Jul 2014 | type 2 diabetes mellitus | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT01131182 Comparator | Jun → Nov 2010 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 4 | NCT01022762 Comparator | Nov 2009 → Nov 2010 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00780715 Comparator | Dec 2008 → Oct 2009 | type 2 diabetes mellitus | University of Dundee | Completed | No outcome recorded |
| — | NCT06222476 Comparator | Feb 2024 → May 2025 | diabetic kidney disease | Yan Bi | Unknown | No outcome recorded |
| — | NCT02879409 Background | Nov 2016 → Oct 2023 overdue | type 2 diabetes mellitus | Weill Cornell Medical College in Qatar | Active not recruiting | No outcome recorded |
| — | NCT01771185 Comparator | Oct 2012 → Oct 2013 | type 2 diabetes mellitus | University of Sao Paulo | Unknown | No outcome recorded |
| — | NCT00147836 Comparator | Sep 2004 → Oct 2007 | type 2 diabetes mellitus | Sun Yat-sen University | Completed | No outcome recorded |
Evidence & citations 26 cited values
Every value below carries the sentence it was read from. 54 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gliclazide | “The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or miconizied equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4...” NCT00379769 ↗52“Vildagliptin 50mg twice/d as add-on to metformin alone over 18 months compared to an add-on therapy with gliclazide 30mg max 4x/d(metformin - gliclazide).” NCT01426737 ↗ “the basis of the conventional therapy will be proposed to be sulfonyl urea drugs (i.e. Gliclazide - Diamicron®, 30 mg, not more than twice daily).” NCT00830297 ↗ “This Arm will include patients receiving Sulphonylureas (Gliclazide/ Glipizide/ Glimepiride/ Tolbutamide) according to the physician's choice.” NCT06449235 ↗ “Sulfonylurea (glibenclamide, glimepiride, or gliclazide) administered orally daily over the Ramadan period as per physician's prescription” NCT01131182 ↗ “with metformin hydrochloride, Glucophage 500mg bid and gliclazide modified release tablets, Diamicron modified release(MR) tablets 60mg qd” NCT02526810 ↗ “If the patients fail to achieve the target, gliclazide-MR (Diamicron, Servier), or glimepiride (Amaryl, Sanofi-Aventis) would be added.” NCT00978263 ↗ “Blood Sugar Control: Medications such as repaglinide tablets (1.0 mg qd) or gliclazide modified-release tablets (30 mg qd) can be used.” NCT06796660 ↗ “OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin).” NCT01584232 ↗ “a sulfonylurea (5-15 mg glibenclamide, 2-6 mg glimepiride, or 30-120 mg gliclazide, in accordance with local practice)” PMID 28917544 ↗ Sep 2017 “Pre-study sulfonylurea therapy consisted of either glibenclamide, glimepiride or gliclazide.” NCT01340768 ↗ |
| Known as | Bilxona | ChEMBL registry synonym — accepted as the source's own label CHEMBL427216 ↗ |
| Known as | Dacadis mr | ChEMBL registry synonym — accepted as the source's own label CHEMBL427216 ↗ |
| Known as | Diaglyk | ChEMBL registry synonym — accepted as the source's own label CHEMBL427216 ↗ |
| Known as | Diamicron | “the basis of the conventional therapy will be proposed to be sulfonyl urea drugs (i.e. Gliclazide - Diamicron®, 30 mg, not more than twice daily).” NCT00830297 ↗3“If the patients fail to achieve the target, gliclazide-MR (Diamicron, Servier), or glimepiride (Amaryl, Sanofi-Aventis) would be added.” NCT00978263 ↗ “the patients with 20 kg/m2\<BMI≤25kg/m2 were initiated with Gliclazide (Diamicron, Servier) 80mg Bid (maximum to 160mg Bid)” NCT00147836 ↗ “tablets containing gliclazide 80 mg (Diamicron® 80 mg)” NCT02777671 ↗ |
| Known as | Diamicron mr | ChEMBL registry synonym — accepted as the source's own label CHEMBL427216 ↗ |
| Known as | Edicil | ChEMBL registry synonym — accepted as the source's own label CHEMBL427216 ↗ |
| Known as | Gliclazida | ChEMBL registry synonym — accepted as the source's own label CHEMBL427216 ↗ |
| Known as | gliclazide MR | “basal long-acting insulin Basaglar/Lantus with gliclazide MR 60 mg OD” NCT03819790 ↗ |
| Known as | gliclazide sustained-release tablets | “This study compares the efficacy and safety of sitagliptin phosphate combined with gliclazide sustained-release tablets versus metformin in treatment-naïve patients with type 2...” NCT06613750 ↗ |
| Known as | Glimicron | ChEMBL registry synonym — accepted as the source's own label CHEMBL427216 ↗ |
| Known as | Glimil | ChEMBL registry synonym — accepted as the source's own label CHEMBL427216 ↗ |
| Known as | J3.151H | ChEMBL registry synonym — accepted as the source's own label CHEMBL427216 ↗ |
| Known as | Nazdol mr | ChEMBL registry synonym — accepted as the source's own label CHEMBL427216 ↗ |
| Known as | NSC-758673 | ChEMBL registry synonym — accepted as the source's own label CHEMBL427216 ↗ |
| Known as | S-1702 | ChEMBL registry synonym — accepted as the source's own label CHEMBL427216 ↗ |
| Known as | S-852 | ChEMBL registry synonym — accepted as the source's own label CHEMBL427216 ↗ |
| Known as | SE 1702 | ChEMBL registry synonym — accepted as the source's own label CHEMBL427216 ↗ |
| Known as | Vamju | ChEMBL registry synonym — accepted as the source's own label CHEMBL427216 ↗ |
| Known as | Vitile xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL427216 ↗ |
| Known as | Ziclaseg | ChEMBL registry synonym — accepted as the source's own label CHEMBL427216 ↗ |
| Known as | Zicron | ChEMBL registry synonym — accepted as the source's own label CHEMBL427216 ↗ |
| Known as | Zicron pr | ChEMBL registry synonym — accepted as the source's own label CHEMBL427216 ↗ |
| Action | Inhibit | “A recent in vitro molecular study suggested that the minor haplotype (K23/A1369) of KATP channel is sensitive to inhibition by gliclazide (binds to A-site) but not...” NCT02201602 ↗ |
| Modality | Small molecule | “sulphonylurea drug” NCT00738088 ↗ |
| Route | Oral | “In oral hpoglycemic agents group, the patients with 20 kg/m2\<BMI≤25kg/m2 were initiated with Gliclazide” NCT00147836 ↗ |